H Lundbeck AS (PK)【HLBBF】銘柄情報

H Lundbeck AS (PK) (HLBBF) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

6.60

( - )

買値

6.01

売値

7.10

出来高

平均取引量 (3 か月)

US$ 692,656

財務取引量

0.00 日の範囲 0.00

5.15 52 週間の範囲 7.55

時価総額

6.542B

企業価値

50.955B

前日終値

6.60

始値

時刻

最終取引時間

VWAP

歳入

25.52B

純利益

3.73B

発行済株式数

991,227,477

浮動株比率 (%)

30.74%

機関投資家保有比率 (%)

78.47%

配当利回り

1.15 (2.78%)

PER

11.64

株価売上高倍率 (PSR)

1.65

1 株当たり利益 (EPS)

3.76

ベータ

0.26

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I d... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark. 詳細を表示

セクター

業界

ウェブサイト

www.lundbeck.com

本社

Valby, Denmark

設立

2026

H Lundbeck AS (PK) is listed in the sector of the その他OTC with ticker HLBBF. The last closing price for H Lundbeck AS (PK) was US$6.60. Over the last year, H Lundbeck AS (PK) shares have traded in a share price range of US$ 5.15 to US$ 7.55.

H Lundbeck AS (PK) currently has 991,227,477 shares in issue. The market capitalisation of H Lundbeck AS (PK) is US$6.54 billion. H Lundbeck AS (PK) has a price to earnings ratio (PE ratio) of 11.64.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	6.6	6.6	6.6	700	6.6	CS
12	-0.3	-4.34782608696	6.9	7.29	6.55	431	6.9117268	CS
26	-0.23	-3.36749633968	6.83	7.29	5.7	678	6.39890908	CS
52	0.65	10.9243697479	5.95	7.55	5.15	743	6.75899481	CS
156	2.15	48.3146067416	4.45	7.55	4.415	893	6.03972669	CS
260	1.81	37.7870563674	4.79	7.55	2	852	5.75492824	CS